A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep; 117(1):83-9.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemokine CXCL10
Chemokine CXCL9
Cytotoxicity, Immunologic
Enzyme-Linked Immunosorbent Assay
Female
Humans
Interferon-gamma
Interleukin-2
Killer Cells, Natural
Middle Aged
Receptor, ErbB-2
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger
Salvage Therapy
Trastuzumab

authors with profiles

Gini Fleming